Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Burden of postmenopausal breast cancer attributable to excess body weight, comparative study of body mass index and CUN-BAE in MCC-Spain study

  • Cubelos-Fernández, Naiara
  • Davila-Batista, Veronica|||0000-0001-8888-395X
  • Fernández-Villa, Tania|||0000-0002-9049-3026
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • Pérez-Gómez, Beatriz|||0000-0002-4299-8214
  • Amiano, Pilar
  • Ardanaz, Eva
  • Delgado Sillero, Irene
  • Llorca, Javier|||0000-0001-8569-861X
  • Tardón, Guillermo Fernández
  • Alguacil, Juan|||0000-0003-2703-9725
  • Vanaclocha Espí, Mercedes|||0000-0002-7202-2861
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Moreno Aguado, Victor Raul|||0000-0002-2818-5487
  • Aragonés, Nuria
  • Dorronsoro, Ane
  • Guevara, Marcela|||0000-0001-9242-6364
  • Reguero Celada, Sofía
  • Pollán, Marina|||0000-0002-4328-1565
  • Martín, Vicente|||0000-0003-0552-2804
10% of postmenopausal breast cancer cases are attributed to a high body mass index (BMI). BMI underestimates body fat, particularly in older women, and therefore the cancer burden attributable to obesity may be even higher. However, this is not clear. CUN-BAE (Clínica Universidad de Navarra-Body Adiposity Estimator) is an accurate validated estimator of body fat, taking into account sex and age. The objective of this study was to compare the burden of postmenopausal breast cancer attributable to excess body fat calculated using BMI and CUN-BAE. This case-control study included 1033 cases of breast cancer and 1143 postmenopausal population controls from the multicase-control MCC-Spain study. Logistic regression models were used to calculate odds ratios (ORs). The population attributable fraction (PAF) of excess weight related to breast cancer was estimated with both anthropometric measures. Stratified analyses were carried out for hormone receptor type. Excess body weight attributable to the risk of breast cancer was 23.0% when assessed using a BMI value ≥30 kg/m 2 and 38.0% when assessed using a CUN-BAE value of ≥40% body fat. Hormone receptor stratification showed that these differences in PAFs were only observed in hormone receptor positive cases, with an estimated burden of 19.9% for BMI and 41.9% for CUN-BAE. These findings suggest that the significance of excess body fat in postmenopausal hormone receptor positive breast cancer could be underestimated when assessed using only BMI. Accurate estimation of the cancer burden attributable to obesity is crucial for planning effective prevention initiatives.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

MicroRNA-200, associated with metastatic breast cancer, promotes traits of mammary luminal progenitor cells

  • Sánchez-Cid, Lourdes
  • Pons, Mònica
  • Lozano, Juan José
  • Rubio, Nuria
  • Guerra-Rebollo, Marta
  • Soriano, Aroa|||0000-0001-9659-1471
  • Paris-Coderch, Laia
  • Segura, Miquel F.
  • Fueyo Arévalo, Raquel
  • Arguimbau, Judit
  • Zodda, Erika
  • Bermudo, Raquel
  • Alonso, Immaculada
  • Caparrós, Xavier
  • Cascante, Marta
  • Rafii, Arash
  • Kang, Yibin
  • Martínez-Balbás, Marian
  • Weiss, Stephen J.
  • Blanco Fernández, Jerónimo
  • Muñoz, Montserrat
  • Fernández, Pedro Luis|||0000-0002-8618-4597
  • Thomson, Timothy M.
MicroRNAs are critical regulators of gene networks in normal and abnormal biological processes. Focusing on invasive ductal breast cancer (IDC), we have found dysregulated expression in tumor samples of several microRNAs, including the miR-200 family, along progression from primary tumors to distant metastases, further reflected in higher blood levels of miR-200b and miR-7 in IDC patients with regional or distant metastases relative to patients with primary node-negative tumors. Forced expression of miR-200s in MCF10CA1h mammary cells induced an enhanced epithelial program, aldehyde dehydrogenase (ALDH) activity, mammosphere growth and ability to form branched tubuloalveolar structures while promoting orthotopic tumor growth and lung colonization in vivo. MiR-200s also induced the constitutive activation of the PI3K-Akt signaling through downregulation of PTEN, and the enhanced mammosphere growth and ALDH activity induced in MCF10CA1h cells by miR-200s required the activation of this signaling pathway. Interestingly, the morphology of tumors formed in vivo by cells expressing miR-200s was reminiscent of metaplastic breast cancer (MBC). Indeed, the epithelial components of MBC samples expressed significantly higher levels of miR-200s than their mesenchymal components and displayed a marker profile compatible with luminal progenitor cells. We propose that microRNAs of the miR-200 family promote traits of highly proliferative breast luminal progenitor cells, thereby exacerbating the growth and metastatic properties of transformed mammary epithelial cells.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Alkylphenolic compounds and risk of breast and prostate cancer in the MCC-Spain study

  • Peremiquel-Trillas, Paula
  • Benavente, Yolanda|||0000-0003-1422-4614
  • Martín-Bustamante, Mayte
  • Casabonne, Delphine
  • Pérez-Gómez, Beatriz|||0000-0002-4299-8214
  • Gomez-Acebo, Ines|||0000-0001-8793-8314
  • Oliete-Canela, Anna
  • Diéguez-Rodríguez, Marta
  • Tusquets, Ignasi
  • Amiano, Pilar
  • Mengual, Lourdes
  • Ardanaz, Eva
  • Capelo, Rocío
  • Molina de la Torre, Antonio José
  • Salas Trejo, Dolores
  • Fernández-Tardon, Guillermo|||0000-0002-7680-158X
  • Lope, Virginia
  • Jimenez-Moleon, José J.
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Dierssen-Sotos, Trinidad|||0000-0002-6127-0077
  • Azpiri, Mikel
  • Muñoz, Montse
  • Guevara, Marcela|||0000-0001-9242-6364
  • Fernández-Villa, Tania|||0000-0002-9049-3026
  • Molina-Barceló, Ana|||0000-0001-5113-6475
  • Aragonés, Nuria
  • Pollán, Marina|||0000-0002-4328-1565
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • Alguacil, Juan|||0000-0003-2703-9725
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • De Sanjose, Silvia|||0000-0002-5909-676X
  • Costas, Laura
Background: Alkylphenolic compounds are chemicals with endocrine disrupting properties that have been widely used in industry with important changes in their usage over time. Few epidemiologic studies have evaluated the effect of alkylphenolic compounds on human health. Objectives: We investigated whether occupational exposure to alkylphenolic compounds is associated with breast and prostate cancer. Methods: We carried out a population-based case-control study including 1513 incident cases of breast cancer, 1095 of prostate cancer, and 3055 controls, frequency matched by sex, age and region. Occupational exposure to alkylphenolic compounds was estimated using a recently developed job-exposure matrix, which considered different scenarios of exposure and different subtypes of alkylphenolic compounds. Results: History of occupational exposure to alkylphenolic compounds was modestly associated with breast cancer (OR = 1.23; 95% CI = 1.01-1.48). Within the different scenarios, the occupational use of domestic tensioactives was positively associated with breast cancer (OR = 1.28; 95% CI = 1.02-1.60), while occupational exposure in other scenarios showed mostly a suggestion of a similar positive associations. Exposure to nonylphenol ethoxylates was positively associated with breast cancer (OR = 1.21; 95% CI = 1.00-1.47), while exposure to other compounds was uncommon. In general, we did not observe associations between alkylphenolic compounds and prostate cancer, except for a positive association among men occupationally exposed to cosmetic, hair and personal hygiene products. Conclusions: Our findings suggest a modest association between breast cancer risk and occupational exposure to alkylphenolic compounds, and no associations between these compounds and prostate cancer risk. These findings warrant further corroboration in other studies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Agreement among Mediterranean Diet Pattern Adherence Indexes, MCC-Spain Study

  • Olmedo-Requena, Rocío|||0000-0003-0054-6700
  • González-Donquiles, Carmen
  • Davila-Batista, Veronica|||0000-0001-8888-395X
  • Romaguera, Dora|||0000-0002-5762-8558
  • Castelló, Adela|||0000-0002-1308-9927
  • Molina de la Torre, Antonio José
  • Amiano, Pilar
  • Dierssen-Sotos, Trinidad|||0000-0002-6127-0077
  • Guevara, Marcela|||0000-0001-9242-6364
  • Fernández-Tardon, Guillermo|||0000-0002-7680-158X
  • Lozano-Lorca, Macarena|||0000-0001-5282-814X
  • Alguacil, Juan|||0000-0003-2703-9725
  • Peiró, Rosana|||0000-0003-1525-4030
  • Huerta, José María|||0000-0002-9637-3869
  • Gracia-Lavedan, Esther
  • Aragonés, Nuria
  • Fernández-Villa, Tania|||0000-0002-9049-3026
  • Solans, Marta|||0000-0002-2397-0435
  • Gomez-Acebo, Ines|||0000-0001-8793-8314
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Pollán, Marina|||0000-0002-4328-1565
  • Martín, Vicente|||0000-0003-0552-2804
There are many different methods used to measure the degree of adherence to a Mediterranean diet (MD), limiting comparison and interpretation of their results. The concordance between different methodologies has been questioned and their evaluation recommended. The aim of this study was to evaluate the agreement among five indexes that measure adherence to a Mediterranean dietary pattern. The study population included healthy adults selected in the Multi-Case Control Spain (MCC-Spain) study recruited in 12 provinces. A total of 3640 controls were matched to cases by age and sex. To reach the aim, the following scores of adherence to a Mediterranean dietary pattern were calculated: Mediterranean diet score (MDS), alternative Mediterranean diet (aMED), relative Mediterranean diet (rMED), dietary score (DS) and literature-based adherence score (LBAS). The relative frequency of subjects with a high level of adherence to a MD varied from 22% (aMED index) to 37.2% (DS index). Similarly, a high variability was observed for the prevalence of a low level of MD: from 24% (rMED) to 38.4% (aMED). The correlation among MDS, aMED and rMED indexes was moderate, except for MDS and aMED with a high coefficient of correlation 0.75 (95% CI 0.74-0.77). The Cohen's Kappa coefficient among indexes showed a moderate-fair concordance, except for MDS and aMED with a 0.56 (95% CI 0.55-0.59) and 0.67 (95% CI 0.66-0.68) using linear and quadratic weighting, respectively. The existing MD adherence indexes measured the same, although they were based on different constructing algorithms and varied in the food groups included, leading to a different classification of subjects. Therefore, concordance between these indexes was moderate or low.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Validating a breast cancer score in Spanish women. The MCC-Spain study

  • Dierssen-Sotos, Trinidad|||0000-0002-6127-0077
  • Gomez-Acebo, Ines|||0000-0001-8793-8314
  • Palazuelos, Camilo
  • Fernández-Navarro, Pablo|||0000-0001-9427-2581
  • Altzibar, Jone M.
  • González-Donquiles, Carmen
  • Ardanaz, Eva
  • Bustamante, Mariona|||0000-0003-0127-2860
  • Alonso Molero, Jessica|||0000-0002-1939-8798
  • Vidal, Carmen|||0000-0003-2768-2710
  • Bayo-Calero, Juan
  • Tardón, Adonina|||0000-0001-5150-1209
  • Salas, Dolores|||0000-0003-0064-1222
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Morros, Rosa|||0000-0001-6752-8748
  • Rodriguez-Cundin, Paz
  • Vinyals, Gemma Castaño
  • Ederra, María
  • Vilorio-Marqués, Laura
  • Amiano, Pilar
  • Pérez-Gómez, Beatriz|||0000-0002-4299-8214
  • Aragonés, Nuria
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Pollán, Marina|||0000-0002-4328-1565
  • Llorca, Javier|||0000-0001-8569-861X
A breast-risk score, published in 2016, was developed in white-American women using 92 genetic variants (GRS92), modifiable and non-modifiable risk factors. With the aim of validating the score in the Spanish population, 1,732 breast cancer cases and 1,910 controls were studied. The GRS92, modifiable and non-modifiable risk factor scores were estimated via logistic regression. SNPs without available genotyping were simulated as in the aforementioned 2016 study. The full model score was obtained by combining GRS92, modifiable and non-modifiable risk factor scores. Score performances were tested via the area under the ROC curve (AUROC), net reclassification index (NRI) and integrated discrimination improvement (IDI). Compared with non-modifiable and modifiable factor scores, GRS92 had higher discrimination power (AUROC: 0.6195, 0.5885 and 0.5214, respectively). Adding the non-modifiable factor score to GRS92 improved patient classification by 23.6% (NRI = 0.236), while the modifiable factor score only improved it by 7.2%. The full model AUROC reached 0.6244. A simulation study showed the ability of the full model for identifying women at high risk for breast cancer. In conclusion, a model combining genetic and risk factors can be used for stratifying women by their breast cancer risk, which can be applied to individualizing genetic counseling and screening recommendations.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Use of Antihypertensive Medication and the Risk of Breast Cancer in a Case-Control Study in a Spanish Population, The MCC-Spain Study

  • Gomez-Acebo, Ines|||0000-0001-8793-8314
  • Dierssen-Sotos, Trinidad|||0000-0002-6127-0077
  • Palazuelos, Camilo
  • Pérez-Gómez, Beatriz|||0000-0002-4299-8214
  • Lope, Virginia
  • Tusquets, Ignasi
  • Alonso, María Henar
  • Moreno Aguado, Victor Raul|||0000-0002-2818-5487
  • Amiano, Pilar
  • Molina de la Torre, Antonio José
  • Barricarte, Aurelio
  • Tardón, Adonina|||0000-0001-5150-1209
  • Camacho, Antonio
  • Peiro-Perez, Rosana
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Muñoz, Montse
  • Michelena-Echeveste, Maria Jesus
  • Ortega Valin, Luis
  • Guevara, Marcela|||0000-0001-9242-6364
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • Aragonés, Nuria
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Pollán, Marina|||0000-0002-4328-1565
  • Llorca, Javier|||0000-0001-8569-861X
The evidence on the relationship between breast cancer and different types of antihypertensive drugs taken for at least 5 years is limited and inconsistent. Furthermore, the debate has recently been fueled again with new data reporting an increased risk of breast cancer among women with a long history of use of antihypertensive drugs compared with nonusers. In this case-control study, we report the antihypertensive drugs-breast cancer relationship in 1,736 breast cancer cases and 1,895 healthy controls; results are reported stratifying by the women's characteristics (i.e., menopausal status or body mass index category) tumor characteristics and length of use of antihypertensive drugs. The relationship among breast cancer and use of calcium channel blockers (CCB) for 5 or more years had odds ratio (OR) = 1.77 (95% CI, 0.99 to 3.17). Stratifying by BMI, the OR increased significantly in the group with BMI ≥ 25 (OR 2.54, 95% CI, 1.24 to 5.22). CCBs were even more strongly associated with more aggressive tumors, (OR for invasive tumors = 1.96, 95% CI = 1.09 to 3.53; OR for non ductal cancers = 3.97, 95% CI = 1.73 to 9.05; OR for Erbb2+ cancer = 2.97, 95% CI: 1.20 to 7.32). On the other hand, premenopausal women were the only group in which angiotensin II receptor blockers may be associated with breast cancer (OR = 4.27, 95% CI = 1.32 to 13.84) but this could not be identified with any type or stage. Use of angiotensin-converting-enzyme inhibitors, beta blockers and diuretics were not associated with risk. In this large population-based study we found that long term use of calcium channel blockers is associated with some subtypes of breast cancer (and with breast cancer in overweight women).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Use of non-steroidal anti-inflammatory drugs and risk of breast cancer, The Spanish Multi-Case-control (MCC) study

  • Dierssen-Sotos, Trinidad|||0000-0002-6127-0077
  • Gomez-Acebo, Ines|||0000-0001-8793-8314
  • de Pedro, María
  • Pérez-Gómez, Beatriz|||0000-0002-4299-8214
  • Servitja, Sonia|||0000-0001-6988-4519
  • Morros, Rosa|||0000-0001-6752-8748
  • Amiano, Pilar
  • Fernández-Villa, Tania|||0000-0002-9049-3026
  • Barricarte, Aurelio
  • Tardón, Adonina|||0000-0001-5150-1209
  • Diaz-Santos, Marian
  • Peiro-Perez, Rosana
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Lope, Virginia
  • Gracia-Lavedan, Esther
  • Alonso, M. Henar
  • Michelena-Echeveste, Maria Jesus
  • García Palomo, Andrés|||0000-0002-9159-9025
  • Guevara, Marcela|||0000-0001-9242-6364
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • Aragonés, Nuria
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Pollán, Marina|||0000-0002-4328-1565
  • Llorca, Javier|||0000-0001-8569-861X
The relationship between non-steroidal anti-inflammatory drug (NSAID) consumption and breast cancer has been repeatedly studied, although the results remain controversial. Most case-control studies reported that NSAID consumption protected against breast cancer, while most cohort studies did not find this effect. Most studies have dealt with NSAIDs as a whole group or with specific drugs, such aspirin, ibuprofen, or others, but not with NSAID subgroups according to the Anatomical Therapeutic Chemical Classification System; moreover, scarce attention has been paid to their effect on different tumor categories (i.e.: ductal/non-ductal, stage at diagnosis or presence of hormonal receptors). In this case-control study, we report the NSAID - breast cancer relationship in 1736 breast cancer cases and 1895 healthy controls; results are reported stratifying by the women's characteristics (i.e.: menopausal status or body mass index category) and by tumor characteristics. In our study, NSAID use was associated with a 24 % reduction in breast cancer risk (Odds ratio [OR] = 0.76; 95 % Confidence Interval [CI]: 0.64-0.89), and similar results were found for acetic acid derivatives, propionic acid derivatives and COXIBs, but not for aspirin. Similar results were found in postmenopausal and premenopausal women. NSAID consumption also protected against hormone + or HER2+ cancers, but not against triple negative breast cancers. The COX-2 selectivity showed an inverse association with breast cancer (i.e. OR < 1), except in advanced clinical stage and triple negative cancers. Most NSAIDs, but not aspirin, showed an inverse association against breast cancer; this effect seems to be restricted to hormone + or HER2+ cancers. The online version of this article (doi:10.1186/s12885-016-2692-4) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets

  • Karube, K.
  • Enjuanes, Anna|||0000-0002-4679-6687
  • Dlouhy, Iván|||0000-0003-3066-4732
  • Jares, Pedro
  • Martín-García, David|||0000-0002-0289-5915
  • Nadeu, Ferran|||0000-0003-2910-9440
  • Ordóñez, G.R.
  • Rovira, Jordi|||0000-0001-8737-5005
  • Clot, Guillem|||0000-0003-2588-7413
  • Royo, C.
  • Navarro, Alba|||0000-0002-4041-0974
  • González Farré, Blanca|||0000-0002-1796-7248
  • Vaghefi, A.
  • Castellano, Giancarlo|||0000-0002-5715-7733
  • Rubio-Perez, C.
  • Tamborero, David
  • Briones Meijide, Javier|||0000-0003-2750-3735
  • Salar Silvestre, Antonio|||0000-0002-4652-4825
  • Sancho, Juan-Manuel|||0000-0001-7168-6538
  • Mercadal, Santiago|||0000-0003-4741-7885
  • Gonzalez-Barca, E.
  • Escoda, Lourdes|||0000-0003-3288-9716
  • Miyoshi, H.
  • Ohshima, K.
  • Miyawaki, K.
  • Kato, K.
  • Akashi, K.
  • Mozos, Ana|||0000-0002-3350-1827
  • Colomo, Luis|||0000-0001-5236-5085
  • Alcoceba, Miguel|||0000-0002-3819-4846
  • Valera, A.
  • Carrió, A.
  • Costa, Dolors|||0000-0002-8276-3292
  • Lopez-Bigas, N.
  • Schmitz, R.
  • Staudt, L.M.
  • Salaverria, I.
  • López Guillermo, Armando|||0000-0002-8588-8381
  • Campo, Elias|||0000-0001-9850-9793
Genome studies of diffuse large B-cell lymphoma (DLBCL) have revealed a large number of somatic mutations and structural alterations. However, the clinical significance of these alterations is still not well defined. In this study, we have integrated the analysis of targeted next-generation sequencing of 106 genes and genomic copy number alterations (CNA) in 150 DLBCL. The clinically significant findings were validated in an independent cohort of 111 patients. Germinal center B-cell and activated B-cell DLBCL had a differential profile of mutations, altered pathogenic pathways and CNA. Mutations in genes of the NOTCH pathway and tumor suppressor genes (TP53/CDKN2A), but not individual genes, conferred an unfavorable prognosis, confirmed in the independent validation cohort. A gene expression profiling analysis showed that tumors with NOTCH pathway mutations had a significant modulation of downstream target genes, emphasizing the relevance of this pathway in DLBCL. An in silico drug discovery analysis recognized 69 (46%) cases carrying at least one genomic alteration considered a potential target of drug response according to early clinical trials or preclinical assays in DLBCL or other lymphomas. In conclusion, this study identifies relevant pathways and mutated genes in DLBCL and recognizes potential targets for new intervention strategies.